Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

New Zealand Prime Minister Jacinda Ardern at an Auckland mall, on the eve of her Labour Party's Oct. 17 election win — a vote of confidence in her handling of the pandemic. She lifted domestic restrictions last month after modeling showed the second Auckland outbreak was elimated. Photo: Hannah Peters/Getty Images

The World Health Organization praised New Zealand on Thursday for its "unique," targeted modeling technology and rapid COVID-19 genome sequencing that's seen the country avoid a lockdown last week despite having four current community cases.

Why it matters: Coronavirus restrictions are growing across the U.S. and Europe, while NZ neighbor South Australia is under a strict lockdown. Geneticist Mike Bunce told Axios that genomic sequencing was "key" to the NZ government's decision not to reimpose restrictions beyond a mask mandate for some travel, effective Thursday.

  • Mathematical and hypothetical modeling that can predict down to the suburb where the virus might spread is helping the Health Ministry "prioritise areas for focus in the public health response to cases and clusters," said NZ Public Health Director Caroline McElnay in an emailed statement.
  • The WHO said in a statement to Axios that whole genome sequencing has been an effective approach in assisting with contact tracing in several countries. NZ using it "may not be unique but combining it with their recently developed modeling data system is, and it appears at this stage to be part of an effective approach to helping reduce and control community transmission.
"It is encouraging to see such technologies and approaches being brought together, and this may be a stimulus for the development and implementation of more effective contact tracing methods to control COVID-19."

Driving the news: The Institute of Environmental Science and Research's (ESR) rapid genomic sequencing has linked all of New Zealand's current cases to an Auckland quarantine hotel for residents newly returned from abroad.

  • Virologist Jemma Geoghegan, who leads this sequencing drive, noted to Axios in an interview that Te Pūnaha Matatini's model "can estimate how big the likely cluster might be if you detect one community case."
  • "That's revised when the genomes are linked because it's likely there are only a few transitions in cases between the worker in this community case," said the University of Otago lecturer.
  • In the most recent community case, the "genomes were identical," indicating it's limited, so Auckland could avoid a lockdown.

Worth noting: Steve Simms, who owns Birkenhead Brewing Company in Auckland said in an interview he's amazed by how fast the government is "using the scientists' knowledge to keep the economy going without major disruption" — noting his firm's takings are "way, way up on last year."

  • That's despite the government imposing one of the world's toughest lockdowns earlier this year and less severe restrictions after an August outbreak contained to Auckland, which saw his business limited to takeaway and deliveries. Government subsidies helped, Simms said.

The big picture: The government has this year provided the ESR sequencing program with NZ$600,000 (U.S.$416,000) and allocated $1.5 million to Te Pūnaha Matatini for its modeling and toward supporting other projects, including genomic work.

  • Both areas of research have been instrumental in the government's pandemic response, along with a strict border policy, managed quarantine of returning NZ travelers, who stay in hotels for two weeks, extensive testing and contact-tracing.
  • Viral PCR tests designed off the genome are "at the heart of our elimination and surveillance strategy," said Bunce, who is the Environmental Protection Authority's chief scientist and author of a report on COVID-19 genomics.

By the numbers: 60 of New Zealand's 64 COVID-19 cases are returned travelers in managed quarantine.

For the record: The mask mandate applies to all people flying in New Zealand and on public transport in Auckland, where the latest outbreak is located.

Go deeper

Jan 30, 2021 - World

Germany to impose travel restrictions to curb spread of coronavirus variants

Border police officers check passports and COVID-19 tests at Frankfurt Airport. Photo: Thomas Lohnes via Getty Images

Germany announced Friday that it was imposing new travel restrictions in an effort to curb the spread of more contagious coronavirus variants.

Details: All non-German residents traveling from countries deemed "areas of variant concern," including the United Kingdom, South Africa, Portugal, Ireland, Brazil, Lesotho and Eswatini, will be banned from entering the country, even if they test negative for the coronavirus.

Jan 29, 2021 - Health

J&J says its one-shot vaccine is 66% effective against moderate to severe COVID

Photo: Thiago Prudêncio/SOPA Images/LightRocket via Getty Images

Johnson & Johnson announced Friday that its single-shot coronavirus vaccine was 66% effective in protecting against moderate to severe COVID-19 disease in Phase 3 trials, which was comprised of nearly 44,000 participants across eight countries.

Between the lines: The vaccine was 72% effective in the U.S., but only 57% effective in South Africa, where a more contagious variant has been spreading. It prevented 85% of severe infections and 100% of hospitalizations and deaths, according to the company.